[Skip to Content]
[Skip to Content Landing]
Article
January 5, 1957

ADENOVIRUS (RI-APC-ARD) VACCINE FOR PREVENTION OF ACUTE RESPIRATORY ILLNESS1. VACCINE DEVELOPMENT

Author Affiliations

Washington, D. C.

From the Department of Respiratory Diseases, Walter Reed Army Institute of Research.

JAMA. 1957;163(1):4-9. doi:10.1001/jama.1957.02970360006002
Abstract

• The immune response was studied in 25 volunteers who received a new bivalent adenovirus vaccine that contained strains of type 4 and type 7 adenovirus. These viruses, obtained originally from patients' throat washings, were adapted to growth in tissue culture of monkey renal epithelium. The virus in the vaccine was killed by incubating with formalin. Responses of the subjects to the vaccine were measured by determining the titer of homotypic neutralizing, heterotypic neutralizing, and adenovirus group complement-fixing antibodies. Nearly all of the subjects gave an antibody response to both virus types, and two injections did not appear to give a higher titer than did a single dose. A striking heterotypic response (to type 3) was found. The maximum antibody levels were reached within two weeks, and the titers were as high as would ordinarily be found after natural infection. No untoward reactions were observed in the recipients.

×